AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NRX Pharmaceuticals, Inc. Director's Dealing 2026

Feb 17, 2026

34346_dirs_2026-02-17_778e8865-799f-4cdf-bcc8-42ca47a4a269.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: NRX Pharmaceuticals, Inc. (NRXP)
CIK: 0001719406
Period of Report: 2026-01-27

Reporting Person: Casper Joseph Michael (Chief Operating Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options (Right to buy)	$2.3900	2036-01-27	Common Stock (100000)		Direct

Footnotes

F1: 33.3% of the stock options shall vest on June 1, 2026, 33.3% shall vest on December 1, 2026, and the remaining 33.3% shall vest on December 1, 2027.